# Yuelei Shen

> Yuelei Shen is a Series A investor at Eucure Biopharma (Boston) backing Biotechnology. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Eucure Biopharma](https://shizune.co/investors/profile/eucure-biopharma)
- Location: Boston, United States
- Total investments: 1
- Last investment: Jun 2022
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/yuelei-shen-608b0b9/

Yuelei Shen is a Series A investor at Eucure Biopharma in Boston focused on Biotechnology. Yuelei Shen - Co-Founder @ Eucure Biopharma

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Doma Biopharmaceutical | Doma Biopharmaceutical is a biotech company. | $142.1M | Series A | Jun 01, 2022 |  |

1 of 1 investments shown.

## Co-investors
- [China Life Private Equity Investment](https://shizune.co/investors/profile/china-life-private-equity-investment) — VC Fund, 1 deal together
- [China Taiping Insurance](https://shizune.co/investors/profile/china-taiping-insurance) — VC Fund, 1 deal together
- [CMB International Capital Corporation](https://shizune.co/investors/profile/cmbi-international-capital-corporation) — VC Fund, 1 deal together
- [PICC Capital Investment Management](https://shizune.co/investors/profile/picc-capital-investment-management) — VC Fund, 1 deal together
- [SDIC Fund Management](https://shizune.co/investors/profile/sdic-fund-management) — VC Fund, 1 deal together
- [Suzhou Industrial Park Assets Management](https://shizune.co/investors/profile/suzhou-industrial-park-assets-management) — VC Fund, 1 deal together

## About Eucure Biopharma

VC Fund · Beijing, China

Eucure Biopharma is a global biotechnology company headquartered in Beijing, China. They are committed to the discovery and development of innovative immuno-oncology targeted antibodies which mainly focus on immune checkpoints. Several products have entered the CMC stage and has applied for clinical trial in 2019. Their mission is to developantibody treatments to improve the survival rate of tumor patients.

3 contacts available at Eucure Biopharma.

| Name | Title | Profile |
| --- | --- | --- |
| Yuelei Shen | Co-Founder | https://shizune.co/investors/profile/yuelei-shen |
| Jian Ni | Co-Founder and President | https://shizune.co/investors/profile/jian-ni |
| Zhihong Li | VP and Chief Regulatory Affairs Officer | https://shizune.co/investors/profile/zhihong-li |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Yuelei Shen invest in?

Yuelei Shen invests primarily in Biotechnology startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Yuelei Shen last invest?

The most recent investment recorded for Yuelei Shen closed in Jun 2022. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co